

Curriculum Vitae

Modified 5/21/20

ALBERTO (Albert) A. MENDIVIL, MD, FACOG, FACS

Hoag Gynecologic Oncology

351 Hospital Road, Suite 507

Newport Beach, CA 92663

Ph: 949-642-1361

Fax: 949-642-1394

alberto.mendivil@hoag.org

www.hoag.org/hgo

PERSONAL:

Date of Birth: January 31, 1975

Place of Birth: Chula Vista, California, USA

Foreign language: Spanish (speak, read, and write)

CURRENT POSITION:

Hoag Gynecologic Oncology

Hoag Specialty Physicians

Co-Director, Hoag Gynecologic Oncology and Complex Pelvic Surgery

5/18/2020 to present

Gynecologic Oncology Associates, Physician and Partner, Newport Beach, CA,

9/8/2010 to 5/17/2020

PROFESSIONAL TRAINING:

Fellowship

Gynecologic Oncology

Department of Obstetrics and Gynecology

University of North Carolina Hospital

CB# 7572

Chapel Hill, NC 27599-7572

PH: 919-966-5996

FAX: 919-843-5387

Fellowship Program Director: John F. Boggess, MD

July 1, 2007 to June 30, 2010

Internship/ Residency
Department of Obstetrics and Gynecology
University of California, Irvine Medical Center
101 The City Drive, Bldg 56, Suite 800
Orange, CA 92868
PH: 714-456-8224
Residency Program Director: Carol A. Major, MD
June 23, 2003 to June 22, 2007

BOARD CERTIFICATION:

American Board of Obstetrics and Gynecology
Gynecologic Oncology, 2013

American Board of Obstetrics and Gynecology
General Obstetrics and Gynecology, 2009

ADVISORY BOARDS:

Abbvie Pharmaceuticals, 4/2020

PROFESSIONAL FELLOWSHIPS:

Fellow of the American Congress of Obstetricians and Gynecologists
Fellow of the American College of Surgeons
Fellow of the Society of Gynecologic Oncology

EDUCATION:

Medical School

University of Utah School of Medicine
Date of Graduation: May 24, 2003
-Degree: M.D.

Undergraduate

University of California, San Diego
Date of Graduation: June 14, 1998
-Degree: Bachelor of Science
-Major: Animal Physiology and Neurosciences
-Minor: Health Care/ Social Issues

PEER REVIEWED PUBLICATIONS/ ABSTRACTS:

Mario M. Leitaó, Benny Brandt, Vasileios Sioulas, Katherine LaVigne, Mark S. Shahin, Destin Black, Jennifer Michelle Scalici, Nathaniel L. Jones, Jubilee Brown, R. Wendel Naumann, Alberto A. Mendivil, Peter C Lim, Leigh Cantrell, Martin A Martino, Valentin Kolev, Charles A. Leath III, Colleen Feltmate, Alexander Olawaiye, Sarah Ferguson, Nadeem Abu-Rustum. The MEMORY Study: Multicenter study of Minimally invasive versus Open Radical hysterectomy in the management of early-stage cervical cancer: survival outcomes. ASCO Annual Meeting 2020 abstract #291389.

Mendivil AA, Chad JA, Goldstein BH. Running out of Time: Facilitating Off Label Approval in Cancer Treatment. *J Clin Pharmacol* 2019; 59: 771-772.

Mendivil AA, Tung PK, Bohart R, Bechtol K, Goldstein BH. Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation. *Gynecol Oncol Rep*. 2018 Sep 10;26:41-44.

Mori KM, Abaid LN, Mendivil AA, Brown III JV, Beck TL, Micha JP, Epstein HD, Goldstein BH. The Incidence of Occult Malignancy Following Uterine Morcellation: A Ten-Year Single Institution Experience Retrospective Cohort Study. *Int J Surg* 2018; 53: 239-242.

Mendivil AA, Abaid LN, Brown III JV, Mori KM, Beck TL, Epstein HD, Micha JP, Goldstein BH. The Safety and Feasibility of Minimally Invasive Sentinel Lymph Node Staging Using Indocyanine Green in the Management of Endometrial Cancer. *Eur J Obstet Gynecol Reprod Biol* 2018; 224: 29-32.

Mendivil AA, Busch JR, Richards DC, Vittori H, Goldstein BH. The Impact of an Enhanced Recovery After Surgery Program on Patients Treated for Gynecologic Cancer in the Community Hospital Setting. *Int J Gynecol Cancer*. 2018 Mar;28(3):581-585.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown III JV, Mori KM, Lopez KL, Goldstein BH. Consolidation Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Advanced Stage Ovarian Carcinoma: A three year experience. *Cancer Chemother Pharmacol* 2017.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Mori KM, Goldstein BH. The impact of total parenteral nutrition on postoperative recovery in patients treated for advanced stage ovarian cancer. *Arch Gynecol Obstet* 2017; 295:439–444.

Mendivil AA, Goldstein BH. Reply: Radical Hysterectomy and Survival Outcomes in the Management of Early Stage Cervical Cancer *Surgical Oncology*. *Surg Oncol*

2016; 25: 123.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, Lopez KL, Goldstein BH. Survival rate comparisons amongst cervical cancer patients treated with an open, robotic-assisted or laparoscopic radical hysterectomy: A five year experience. *Surg Oncol* 2016; 25: 66-71.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, Lopez KL, Goldstein BH. Lower-extremity lymphedema following management for endometrial and cervical cancer. *Surg Oncol.* 2016 Sep; 25(3):200-4.

Micha JP, Rettenmaier MA, Brown III JV, Mendivil AA, Abaid LN, Lopez KL, Goldstein BH. A randomized, controlled pilot study comparing the impact of aprepitant and fosaprepitant on chemotherapy induced nausea and vomiting in patients treated for gynecologic cancer. *Int J Gynecol Cancer.* 2016; 26:389-393.

Rettenmaier MA, Abaid LN, Brown JV 3rd, Mendivil AA, Lopez KL, Goldstein BH. Dramatically reduced incidence of vaginal cuff dehiscence in gynecologic patients undergoing endoscopic closure with barbed sutures: A retrospective cohort study. *Int J Surg* 2015; 19:27-30.

Rettenmaier MA, Mendivil AA, Abaid LN, Brown JV 3rd, Micha JP, Wilcox AM, Goldstein BH. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. *Arch Gynecol Obstet* 2015; 291:1381-6.

Rettenmaier MA, Mendivil AA, Gray CM, Chapman AP, Stone MK, Tinnerman EJ, Goldstein BH. Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of advanced stage ovarian carcinoma. *Int J Hyperthermia* 2015; 24:1-7.

Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, Lopez KL, Goldstein BH. A comparison of open surgery, robotic-assisted surgery and conventional laparoscopic surgery in the treatment of morbidly obese endometrial cancer patients. *JLS* 2015;19: 1-5.

Rettenmaier MA, Mendivil AA, Abaid LN, Brown JV, Wilcox AM, Goldstein BH. Consolidation Hyperthermic Intraperitoneal Chemotherapy and Maintenance Chemotherapy Following Laparoscopic Cytoreductive Surgery in the Treatment of Advanced Stage Ovarian Carcinoma. *Int J Hyperthermia* 2015;31:8-14.

Brown JV, Mendivil AA, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. The Safety and Feasibility of Robotic Lymph Node Staging in Early-Stage Ovarian Cancer. *Int J Gynecol Cancer* 24(8) 2014.

Rettenmaier MA, Abaid LN, Brown JV 3rd, Mendivil AA, Micha JP, Goldstein

BH. The incidence of postprandial nausea and nutritional regression in gynecologic cancer patients following intestinal surgery: A retrospective cohort study. *Int J Surg* 2014; 12: 783-787.

Mendivil AA, Micha JP, Stallman JM, Goldstein BH. A Very Rare Case of Vaginal Angiokeratoma. *Euro J Gynaecol Oncol* 2014; 3: 313-315.

Mendivil AA, Brown III JV, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. Robotic-Assisted Surgery for the Treatment of Pelvic Masses in Pregnant Patients: A Series of Four Cases and Literature Review. *J Robot Surg* 2013; 7: 333–337. *Care* 2013; 2: 124.

Mendivil AA, Cupp JS, Van Dalsem W, Caffarelli A, Goldstein BH. Multidisciplinary treatment of pelvic and cardiac intravenous leiomyosarcomatosis. *Gynecol Oncol* 2013; 6: 16–18.

Mendivil AA, Brown III JV, Abaid LN, Rettenmaier MA, Micha JP, Wabe MA, Goldstein BH. Robotic-Assisted Surgery for the Treatment of Pelvic Masses in Pregnant Patients: A Series of Four Cases and Literature Review. *J Robot Surg* 2013; 7: 333–337.

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. *Cancer Chemother Pharmacol* 2013;72:101-107.

Micha JP, Brown JV, Rettenmaier MA, Abaid LN, Mendivil AA, Lopez KI, Goldstein BH. Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian cancer. *Clin Oncol* 2013; Feb (letter).

Mendivil AA, Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. Increased incidence of severe gastrointestinal events with first-line Paclitaxel, Carboplatin, and Vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. *Int J Gynecol Cancer* 2013;23:533-9.

Mendivil AA, Stallman JM, Chad JN, Goldstein BH. An Unusual Case of Fallopian Intraepithelial Tube Carcinoma with Mucinous Goblet Cell Differentiation. *Gynecol Oncol* 2012; 2: 47-50.

Micha JP, Mendivil AA, Cupp JS, Goldstein BH. Recurrent Lymphatic Ascites in a Patient Cured of Cervical Carcinoma. *Gyn Oncol* 2012; 2: 105-106.

Rettenmaier MA, Mendivil AA, Brown JV III, Abaid LN, Micha JP, Goldstein

BH. Same Day Discharge in Clinical Stage 1 Endometrial Cancer Patients Treated with Total Laparoscopic Hysterectomy, Bilateral Salpingoophorectomy and Bilateral Pelvic Lymphadenectomy. *Oncol* 2012; 82:321-326

Abaid LN, Rettenmaier MA, Brown III JV, Micha JP, Mendivil AA, Wabe MA, Goldstein BH. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. *J Gynecol Oncol* 2012; 23: 22-27.

Mendivil AA, Abaid LN, Epstein HD, Rettenmaier MA, Brown JV III, Micha JP, Wabe MA, Goldstein BH. Paget's Disease of the Vulva: A Clinicopathologic Institutional Review. 2011 *Int J Clin Oncol*, manuscript accepted for publication.

Mendivil A, Rettenmaier MA, Cox C, Abaid LA, Brown JV, Micha JP, Lopez KL, Goldstein BH. Acute and Delayed Complications from Surgery and Adjuvant Radiotherapy in the Treatment of High Risk Endometrial and Cervical Cancer. 2011 *Oncology*, manuscript accepted for publication.

Micha JP, Mendivil A, Epstein HD, LaFlamme LA, Goldstein BH. An Unusual Case of Endometrioid Adenocarcinoma Arising from Endometriosis. 2011 *J Repro Med*, manuscript accepted for publication.

Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Mallory KM, Bae-Jump VL. AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. 2011 *Repro Sci*, manuscript accepted for publication.

Cantrell LA, Mendivil A, Gehrig PA, Boggess JF. Survival Outcomes for Women Undergoing Type III Robotic Radical Hysterectomy for Cervical Cancer: A 3-year experience. 2010 *Gynecol Oncol*, 117(2):260-5.

Cantrell LA, Zhou C, Mendivil A, Gehrig PA, Malloy KM, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. 2009 *Gynecol Oncol*, 116(1): 92-98.

Boggess JF, Gehrig PA, Cantrell LA, Shafer A, Mendivil A, Rossi E, Hanna R. Perioperative outcomes of robotically assisted hysterectomy for benign cases with complex pathology. 2009 *Obstet Gynecol*, 114(3).

Mendivil A, Holloway RW, Boggess JF. Invited Review: Emergence of robotic assisted surgery in gynecologic oncology: American perspective. 2009 *Gynecol Oncol*, 114(2): S24-S31.

Mendivil A, Schuler KM, Gehrig PA. Non-Endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. 2009 *Cancer Control*, 16(1): 46-52.

Gehrig PA, Cantrell LA, Shafer A, Abaid LN, Mendivil A, Boggess JF. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? 2008 *Gynecol Oncol*, 111(1): 41-45.

Yessaian A, Mendivil A, Brewster WR. Population characteristics in cervical cancer trials: Search for external validity. 2005 *Am J Obstet Gynecol*, 192(2): 407-13.

La Cava A, Massa M, Mendivil A, Martini A, Albani S. Genetic Immunization Maps T Cell (Auto) Immune Responses to Self Antigens Homologous to Exogenous Proteins. 2002 *Autoimmunity*, 35(2): 105-10.

Prakken B, Wauben M, Genini D, Samodal R, Barnett J, Mendivil A, Leoni L, Albani S. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. 2000 *Nature Medicine*, 6(12): 1406-10.

CLINICAL RESEARCH STUDIES:

Site principal investigator, A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab in Combination with Chemotherapy Followed by Maintenance Therapy of Avelumab in Combination with The Poly (Adenosine Diphosphate [ADP]-RIBOSE) Polymerase (PARP) Inhibitor Talazoparib in Patients with Previously Untreated Advanced Ovarian Cancer, 2019

Site principal investigator, A randomized, double-blind, phase 3 comparison of platinum-based therapy with TSR 042 and Niraparib versus standard of care platinum-based therapy as first line treatment of stage 3 or 4 nonmucinous epithelial ovarian cancer, 2019

Site sub-investigator, A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Newly Diagnosed Patients with Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma, 2014-2018

Site principal investigator, A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200), 2016-2017

Site principal investigator, A Phase II trial evaluating the efficacy of Akynzeo® in the management of chemotherapy induced nausea and vomiting in patients treated for advanced stage ovarian carcinoma, 2017

Site principal investigator, Phase 1b & 2 Study with GL-ONC1 in Patients with Recurrent Ovarian Cancer (VIRO-15), 2017

Site principal investigator, A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy, 2017

Site principal investigator, A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors, 2017

Site sub-investigator, Feasibility study for establishing epithelial ovarian, fallopian tube or primary peritoneal carcinoma short term cell culture and efficient blood derived dendritic tumor cell antigen loading for cell based immunotherapy, 2017

Site sub-investigator, An open- label, randomized, phase 3 clinical trial of REGN2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinum-refractory cervical carcinoma, 2017

Site principal investigator, A multiple patient early access program for Olaparib tablets for the maintenance treatment following response (complete response or partial response) to platinum-based chemotherapy in patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, 2017

Site principal investigator, A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab (msb0010718c) in combination with and /or following chemotherapy in patients with previously untreated epithelial ovarian cancer, 2016

Site principal investigator, A randomized, multicenter, double-blinded, clinical study to demonstrate the biosimilarity of intravenous GP2019 vs Avastin® (EU-authorized) in combination with Carboplatin and Gemcitabine in relapsed platinum-sensitive ovarian cancer patients, 2016

Site sub-investigator, A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in chemotherapy-naive patients with newly diagnosed stage I-V persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus or ovary, 2015-2017

Site sub-investigator, A randomized Phase IIB evaluation of weekly Paclitaxel (NSC #673089) plus Pazopanib (NSC #737754) (IND #75648) versus weekly Paclitaxel plus placebo in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, 2015-2017

Site sub-investigator, A Phase II evaluation of the potent, highly selective Poly

(ADP-RIBOSE) Polymerase (PARP) -1 AND -2 inhibitor Veliparib (ABT-888) (IND #77840) (NSC #737664) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who carry a GERMLINE BRCA1 OR BRCA2 Mutation, 2014-2016

Site principal investigator, A Phase IV, Randomized, Double-Blinded, Multi-center study comparing the efficacy of Fosaprepitant with standard pre-medications to aprepitant with standard pre-medications for chemotherapy induced nausea and vomiting in patients treated for gynecological cancer, 2014-2016

Site sub-investigator, randomized phase 3 clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy, 2014

Site sub-investigator, A randomized phase 2/3 study of paclitaxel/carboplatin/metformin (nsc#91485) versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage 3 or 4A, stage 4b, or recurrent endometrial cancer, 2014

Site sub-investigator, A phase 2, open-label, non-randomized, pilot study of paclitaxel, carboplatin and oral metformin for patients newly diagnosed with stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, 2014

Site principal investigator, randomized phase II evaluation of carboplatin/paclitaxel with and without trastuzumab (Herceptin®) in her2/neu+ patients with advanced/recurrent uterine serous papillary carcinoma, 2013

Site sub-investigator, A phase I/II, open-label, non-randomized, pilot study of weekly paclitaxel, every four-week carboplatin and oral vorinostat for patients newly diagnosed with stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer, 2010

BOOK CHAPTERS:

Mendivil A, Boggess JF. Robotic Surgery in Gynecologic Oncology. In: Textbook in Gynaecologic Oncology (ESGO ENYGO Endorsed). Edited by Ayhan, Gultekin, Dursun. Publisher: Gunes Kitabevleri, 2011.

Mendivil A, Fowler WC. Early epithelial ovarian cancer. In: Gynecological Cancer Management: Identification, Diagnosis, and Treatment. D Clarke-Pearson, JT Soper (eds) 2009. Publisher: Wiley-Blackwell, 2010

Mendivil A, Bae-Jump VL. Germ cell tumors. In: Gynecological Cancer Management: Identification, Diagnosis, and Treatment. D Clarke-Pearson, JT Soper (eds) 2009. Publisher: Wiley-Blackwell, 2010

Mendivil A, Clarke-Pearson D. Gynecological Cancer Management: Identification, Diagnosis, and Treatment. D Clarke-Pearson, JT Soper (eds) 2009. Publisher: Wiley-Blackwell, 2010

Mendivil A, Boggess JF. Robotic Surgery in Gynecologic Oncology. In: Textbook in Gynaecologic Oncology (ESGO ENYGO Endorsed). Edited by Ayhan, Gultekin, Dursun. Publisher: Gunes Kitabevleri, 2009.

RESEARCH/ POSTER PRESENTATIONS:

Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH: A Phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced stage primary epithelial ovarian, fallopian tube, and peritoneal carcinoma. Abstract presented at the Annual meeting of the Society of Gynecologic Oncology, Austin, TX, March 2012.

Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, and Bae-Jump VL: Rapamycin potentiates the effects of paclitaxel in uterine papillary serous carcinoma (UPSC) cells through inhibition of cell proliferation and induction of apoptosis. Abstract presented at the Annual meeting of the American Association for Cancer Research, Washington, DC, April 2010.

O'Malley DM, Achenbach S, Skaznik-Wikiel M, Nakayama JM, Mendivil A, Havrilesky LJ, Secord AA, DeBernardo R, Gehrig PA, Fader AN: Improved survival with chemotherapy and radiation in advanced-stage uterine clear cell carcinoma. Abstract presented at the Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 2010.

O'Malley DM, Nakayama J, Secord AA, DeBernardo R, Gehrig PA, Fader AN, Mendivil A, Cohn DE, Skaznik-Wikiel M, Havrilesky L: Benefit of Adjuvant Therapy in Early Stage Clear Cell Cancer of the Uterus? Abstract presented at the Annual Meeting of the Society of Gynecologic Oncologists, San Francisco, CA, March 2010.

Mendivil A, Vogel TJ, Gehrig PA: A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer. Abstract presented at the Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 2009.

Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Bae-Jump VL: AMG 479, a novel IGF-1R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. Abstract presented at the Annual Meeting of the American Association for Cancer Research, Denver, CO, April 2009.

Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Bae-Jump VL: AMG 479, a novel IGF-1R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. Abstract presented at the Annual UNC Women's Health Research Day Conference, Chapel Hill, NC, April 2009.

Mendivil A, Cantrell LA, Gehrig PA, Boggess JF: Survival Outcomes for Women Undergoing Robotic Surgery for Endometrial Cancer: A Three-Year Experience. Abstract presented at the Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, February 2009.

Cantrell LA, Mendivil A, Zhou C, Gehrig PA, Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Abstract presented at the 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, February 2009.

Cantrell LA, Mendivil A, Gehrig PA, Boggess JF: Survival Outcomes for Women Undergoing Robotic Surgery for Cervical Cancer: A Three-Year Experience. Abstract presented at the 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, February 2009.

Hanna R, Cantrell LA, Gehrig PA, Mendivil A, Boggess JF: A cost analysis of robotic as compared to conventional laparoscopy for endometrial cancer staging. Abstract presented at the 40th Annual Meeting of the Society of Gynecologic Oncologists, San Antonio, TX, February 2009.

Boggess JF, Shafer A, Cantrell LA, Abaid L, Mendivil A, Gehrig PA: Robotically Assisted Type III Radical Hysterectomy in a Morbidly Obese Woman. Abstract at the 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa Bay, FL, March 2008.

Mendivil A, Hunter MI, Han E, Tewari KS: Management Of Primary Peritoneal And Fallopian Tube Carcinomas In The Platinite-Taxane Era. Abstract at the 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa Bay, FL, March 2008.

Gehrig PA, Cantrell LA, Shafer A, Abaid L, Mendivil A, Boggess JF: What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman? Abstract at the 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa Bay, FL, March 2008.

Hunter MI, Ziogas A, Mendivil A, Brewster WR: Second primary breast cancer after epithelial ovarian cancer and tumors of low malignant potential. Abstract at the 39th Annual Meeting of the Society for Gynecologic Investigation, Los Angeles, CA, April 2005.

Mendivil A, Cole BC, Sawitzke A: Mapping B-cell epitopes on mycoplasma arthritidis mitogen (MAM) using lambda phage display peptide library. Abstract at the Western Student Medical Research Forum, Deer Valley, UT, February 2001.

Prakken B, Samodal R, Mendivil A, Bonnin D, Lanza P, Amox D, Roord S, DeKleer I, Jones M, Carson D, Albani S. An *E. coli* Heat Shock Protein dnaJ Peptide Homologous To The “Shared Epitope” Is A Trigger Of Pro-Inflammatory, TH-1 Type T Cell Responses In Patients With Early Rheumatoid Arthritis (RA). Abstract at the Annual Meeting of the American College of Rheumatology, San Diego, CA, May 1998.

Samodal R, Louie S, Amox D, Bonnin D, Yang X, Weaver B, Mendivil A, Prakken B, Carson D, Albani S. Immunomodulatory Effects Of Treatment With A “Shared Epitope” Peptide In Patients With Rheumatoid Arthritis. Abstract at the Annual Meeting of the American College of Rheumatology, San Diego, CA, May 1998.

LEADERSHIP:

Co-Director, Gynecologic Oncology and Complex Pelvic Surgery, Hoag Hospital, Newport Beach, CA, 2017-present

Physician Director, Robotic Surgery Program, Pomona Valley Hospital Medical Center, Pomona, CA, 2017-2020

Administrative Chief Resident, UCI Medical Center, Dept. of OB/GYN, 2006-2007

ACOG Junior Fellow District IX, Section 7 Chair, 2005-2006

‘Life of Medicine’ undergraduate course co-instructor, UC Irvine, 2005

Student Body Co-President, University of Utah School of Medicine, 2002-2003

Student Advisory Committee, Department of Obstetrics and Gynecology, University of Utah School of Medicine, 2001

Association of Minority Medical Students, University of Utah School of Medicine
Co-President, 1999-2000

National Medical Fellowships, Academy Fellow, University of Utah School of Medicine Representative, 2001-2002

2nd Year Class Co-President, University of Utah School of Medicine, 2000-2001

Executive Committee member, University of Utah School of Medicine, 2000-2001, 2002-2003

Alumni Association Board Member, University of Utah School of Medicine, 2000-2001, 2002-2003

Community Outreach Program Student Coordinator, University of Utah School of Medicine, 2000-2001

International Pharmacy Student Foundation Book Appeal Project, 2000
-Book drive organizing committee chairman (medical school section)
-Over 600 medical books were collected and donated to *Cruz Roja Mexicana* Hospital, Tijuana, Mexico

Medical Spanish Instructor- University of Utah School of Medicine, 1999-2001

AWARDS:

President's Circle Award, Pomona Valley Hospital, 2018
Surgeon of the Year, Hoag Hospital Newport Beach, 2016
Best Fellow Presentation, Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, September, 2008
Philip J. DiSaia, MD UCI Medical Student Teaching Award, June 2007
UCI School of Medicine Resident Teaching Award, June 2007
UCI School of Medicine Resident Teaching Award, June 2005
UCI Dept. of OB/Gyn 2ND Year Resident Teaching Award, June 2005
UCI Dept. of OB/Gyn Teaching Resident of the Month, July 2004
UCI Dept. of Internal Medicine Outpatient Clinic Resident of the Month, July 2003
University of Utah School of Medicine Alumni Association Student Award, 2003
Bristol-Myers Squibb/ NMF Academic Medicine Research Fellowship, 2002
Linda Derrick Wood Scholarship, 2002
The Endocrine Society Research Fellowship, 2002
Herbert W. Nickens, M.D. Minority Medical Student Scholarship, 2001
National Medical Fellowships, Inc. Scholarship, 2001
Western Student Medical Research Award, 2001
Robert Wood Johnson Foundation Award, 2000-2001
Edward C. Klatt, M.D. Scholarship, 2000-2001
Bristol-Myers Squibb/ NMF Academic Medicine Fellowship (Finalist), 2000
Summer Institute for Medical Students, Betty Ford Center, Scholarship, 2000
National Medical Fellowships, Inc. Scholarship, 2000
Medical Student Research Fellowship, U of Utah School of Medicine, 2000
Dean A. Moffat, M.D. Memorial Scholarship, 1999-2000
Bernett Love Memorial Scholarship, 1999-2000
Undergraduate Research Scholar, University of California, San Diego, 1997
Howard Hughes Research Stipend, University of California, San Diego, 1997

Academic Grant, University of California, San Diego, 1993-1994
David Holmgren Memorial Scholarship, 1993

PROFESSIONAL ASSOCIATIONS:

Society of Gynecologic Oncology, 2007-present
American College of Surgeons, 2008-present
American College of Obstetricians and Gynecologists, 2004-present
American Society of Clinical Oncology, 2010-present